Advertisement

Neurourology pp 569-575 | Cite as

Diabetes

  • Abdulrahman Almuhrij
  • Riyad Al Mousa
Chapter

Abstract

Changes in environmental and behavioral factors such as a sedentary life style and obesity over the previous years have resulted in a dramatic increase in the incidence of diabetes worldwide [1]. Urological manifestations of Diabetic patients include: Diabetic Nephropathy, Renal Vascular disease, Urinary Tract Infections, Emphysematous Complications, Infertility, Erectile dysfunction, and Diabetic bladder dysfunction which we will talk about it in details in this section [2, 3].

References

  1. 1.
    Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.CrossRefGoogle Scholar
  2. 2.
    Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–62.CrossRefGoogle Scholar
  3. 3.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.CrossRefGoogle Scholar
  4. 4.
    Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.CrossRefGoogle Scholar
  5. 5.
    Daneshgari F, Moore C. Diabetic uropathy. Semin Nephrol. 2006;26:182.CrossRefGoogle Scholar
  6. 6.
    Olapade-Olaopa EO, Morley RN, Carter CJ, Walmsley BH. Diabetic cystopathy presenting as primary acute urinary retention in a previously undiagnosed young male diabetic patient. J Diabetes Complicat. 1997;11:350–1.CrossRefGoogle Scholar
  7. 7.
    Yuan Z, Tang Z, He C, Tang W. Diabetic cystopathy: a review. J Diabetes. 2015;7:442–7.CrossRefGoogle Scholar
  8. 8.
    Siracusano S, d’Aloia G, Lentini MG, Silvestre G. Diabetic cystopathy. J Diabetes Nutr Meta. 2015;15:41–4.Google Scholar
  9. 9.
    Zderic SA, Chacko S, Disanto ME, Wein AJ. Voiding function: relevant anatomy, physiology, pharmacology, and molecular aspects. Philadelphia: Williams & Wilkins; 2002.Google Scholar
  10. 10.
    Burakgazi AZ, Alsowaity B, Burakgazi ZA, Unal D, Kelly JJ. Bladder dysfunction in peripheral neuropathies. Muscle Nerve. 2012;45:2–8.CrossRefGoogle Scholar
  11. 11.
    Daneshgari F, Liu G. Diabetic bladder dysfunction: current translational knowledge. J Urol. 2009;182:S18–26.CrossRefGoogle Scholar
  12. 12.
    Ueda T, Tamaki M, Kageyama S, Yoshimura N, Yoshida O. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int J Urol. 2000;7:95.CrossRefGoogle Scholar
  13. 13.
    Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol. 1995;153:342.CrossRefGoogle Scholar
  14. 14.
    Brown JS, Nyberg LM, Kusek JW, Burgio KL, Diokno AC, Foldspang A, et al. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on Epidemiologic Issues in Urinary Incontinence in Women. Am J Obstet Gynecol. 2003;188(6):S77.CrossRefGoogle Scholar
  15. 15.
    Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med. 1980;92:318–21.CrossRefGoogle Scholar
  16. 16.
    Yoshimura N, Chancellor MB, Andersson KE, Christ GJ. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 2005;95:733.CrossRefGoogle Scholar
  17. 17.
    Liu G, Daneshgari F. Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. Am J Physiol Renal Physiol. 2005;288:F1220.CrossRefGoogle Scholar
  18. 18.
    Liu G, Daneshgari F. Temporal diabetes- and diuresis-induced remodeling of the urinary bladder in the rat. Am J Physiol Regul Integr Comp Physiol. 2006;291:R837.CrossRefGoogle Scholar
  19. 19.
    Christ GJ, Hsieh Y, Zhao W, Schenk G, Venkateswarlu K, Wang HZ, et al. Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo. BJU Int. 2006;97:1076.CrossRefGoogle Scholar
  20. 20.
    Tammela TL, Leggett RE, Levin RM, Longhurst PA. Temporal changes in micturition and bladder contractility after sucrose diuresis and streptozotocin-induced diabetes mellitus in rats. J Urol. 1995;153:2014.CrossRefGoogle Scholar
  21. 21.
    Poladia DP, Bauer JA. Functional, structural, and neuronal alterations in urinary bladder during diabetes: investigations of a mouse model. Pharmacology. 2005;74:84.CrossRefGoogle Scholar
  22. 22.
    Liu G, Lin Y, Yamada Y, Daneshgari F. External urethral sphincter activity in diabetic rats. Neurourol Urodyn. 2008;27:429.CrossRefGoogle Scholar
  23. 23.
    Torimoto K, Fraser MO, Hirao Y, De Groat WC, Chancellor MB, Yoshimura N. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959.CrossRefGoogle Scholar
  24. 24.
    Ueda T, Yoshimura N, Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol. 1997;157:580.CrossRefGoogle Scholar
  25. 25.
    Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.CrossRefGoogle Scholar
  26. 26.
    Niu X, Wang X, Huang H, Ni P, Lin Y, Shao B. Bulbocavernosus reflex test for diagnosis of pudendal nerve injury in female patients with diabetic neurogenic bladder. Aging Dis. 2016;6:715–20.CrossRefGoogle Scholar
  27. 27.
    Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol. 1994;130:24.CrossRefGoogle Scholar
  28. 28.
    Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role of NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res. 1990;26:258.CrossRefGoogle Scholar
  29. 29.
    Steinbacher BC Jr, Nadelhaft I. Increased level of nerve growth factor in the urinary bladder and hypertrophy of dorsal root ganglion neurons in the diabetic rat. Brain Res. 1988;782:255.CrossRefGoogle Scholar
  30. 30.
    Sasaki K, Michael B. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J Urol. 2002;168:1259–64.CrossRefGoogle Scholar
  31. 31.
    Cheng JT, Yu BC, Tong YC. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocininduced diabetic rats. Neurosci Lett. 2007;423:1–5.CrossRefGoogle Scholar
  32. 32.
    Tong YC, Cheng JT, Wan WC. Effects of Ba-Wei-Die-Huang-Wan on the cholinergic function and protein expression of M2 muscarinic receptor of the urinary bladder in diabetic rats. Neurosci Lett. 2002;330:21–4.CrossRefGoogle Scholar
  33. 33.
    Kubota Y, Nakahara T, Mitani A, Maruko T, Sakamoto K, Ishii K. Augmentation of rat urinary bladder relaxation mediated by beta1-adrenoceptors in experimental diabetes. Eur J Pharmacol. 2003;467:191–5.CrossRefGoogle Scholar
  34. 34.
    Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120:1–34.CrossRefGoogle Scholar
  35. 35.
    Daneshgari F, Huang X, Liu G, Bena J, Saffore L, Powell CT. Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1728.CrossRefGoogle Scholar
  36. 36.
    Daneshgari F, Liu G, Imrey PB. Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J Urol. 2006;176:380.CrossRefGoogle Scholar
  37. 37.
    Beshay E, Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology. 2004;64:1062.CrossRefGoogle Scholar
  38. 38.
    Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212:167.CrossRefGoogle Scholar
  39. 39.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813.CrossRefGoogle Scholar
  40. 40.
    Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615.CrossRefGoogle Scholar
  41. 41.
    Pinna C, Zanardo R, Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur J Pharmacol. 2000;388:267.CrossRefGoogle Scholar
  42. 42.
    Pitre DA, Ma T, Wallace LJ, Bauer JA. Time-dependent urinary bladder remodeling in the streptozotocin-induced diabetic rat model. Acta Diabetol. 2002;39:23.CrossRefGoogle Scholar
  43. 43.
    Berger P, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, et al. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia. 2005;48:784–9.CrossRefGoogle Scholar
  44. 44.
    Ikeda K, Wada Y, Foster HE, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol. 2000;164:180–5.CrossRefGoogle Scholar
  45. 45.
    Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hiperplasia. Prostate. 2010;1(70):79–89.CrossRefGoogle Scholar
  46. 46.
    Longhurst PA. In vivo urinary bladder function in rats following prolonged diabetic and non-diabetic diuresis. Neurourol Urodyn. 1990;9:171.CrossRefGoogle Scholar
  47. 47.
    Satriano J. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids. 2007;33:331.CrossRefGoogle Scholar
  48. 48.
    Brown JS, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y. Incontinence in women with impaired glucose tolerance: results of the Diabetes Prevention Program. J Urol. 2004;171:325–6.CrossRefGoogle Scholar
  49. 49.
    Jackson RA, Vittinghoff E, Kanaya AM, Resnick HE, Kritchevsky S, Miles T, Simonsick E, et al. Aging and body composition. Obstet Gynecol. 2004;104:301–7.CrossRefGoogle Scholar
  50. 50.
    Fayyad AM, Hill SR, Jones G. Prevalence and risk factors for bothersome lower urinary tract symptoms in women with diabetes mellitus from hospital-based diabetes clinic. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1339–44.CrossRefGoogle Scholar
  51. 51.
    Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn. 2007;26:814–9.CrossRefGoogle Scholar
  52. 52.
    Agency for Health Care Policy and Research. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline, vol. 7. Washington, DC: U.S. Public Health Service, Department of Health and Human Services, AHCPR; 1996. p. 19–71.Google Scholar
  53. 53.
    Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:40–3.CrossRefGoogle Scholar
  54. 54.
    Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29:385–90.CrossRefGoogle Scholar
  55. 55.
    Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–63.CrossRefGoogle Scholar
  56. 56.
    Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5–26.CrossRefGoogle Scholar
  57. 57.
    Wein AJ, Van Arsdalen K, Levin RM. Pharmacologic therapy. In: Krane RJ, Siroky MB, editors. Clinical neuro-urology. Boston: Little Brown; 1992. p. 523–57.Google Scholar
  58. 58.
  59. 59.
    Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31:1206.CrossRefGoogle Scholar
  60. 60.
    Daniels DH, Powell CR, Braasch MR, Kreder KJ. Sacral neuromodulation in diabetic patients: Success and complications in the treatment of voiding dysfunction. Neurourol Urodyn. 2010;29:578–81.PubMedPubMedCentralGoogle Scholar
  61. 61.
    van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–34.CrossRefGoogle Scholar
  62. 62.
    Zincke H, Campbell JT, Palumbo PJ, Furlow WL. Neurogenic vesical dysfunction in diabetes mellitus: another look at vesical neck resection. J Urol. 1974;111:488–90.CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Abdulrahman Almuhrij
    • 1
  • Riyad Al Mousa
    • 1
  1. 1.King Fahad Specialist HospitalDammamSaudi Arabia

Personalised recommendations